(E)-6-(3-Cyclopentyloxy-4-methoxy-phenyl)-3,4-dihydro-2H-naphthalen-1-one oxime | 171808-26-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: (E)-6-(3-Cyclopentyloxy-4-methoxy-phenyl)-3,4-dihydro-2H-naphthalen-1-one oxime
• 英文别名: (NE)-N-[6-(3-cyclopentyloxy-4-methoxyphenyl)-3,4-dihydro-2H-naphthalen-1-ylidene]hydroxylamine
• CAS: 171808-26-7
• 化学式: C₂₂H₂₅NO₃
• 分子量: 351.445
• InChiKey: YFQVEZICSAJMNW-BSYVCWPDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  51
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  6-(3-Cyclopentyloxy-4-methoxy-phenyl)-3,4-dihydro-2H-naphthalen-1-one 在 吡啶 、 盐酸羟胺 作用下， 以 二氯甲烷 、 乙酸乙酯 为溶剂， 生成 (E)-6-(3-Cyclopentyloxy-4-methoxy-phenyl)-3,4-dihydro-2H-naphthalen-1-one oxime
  参考文献：
  名称：

  Substituted biphenyl derivatives

  摘要：

  以下结构的化合物：##STR1## 其中，当R.sub.8 =H时：R.sub.1 =烷基、环烷基、芳基烷基、芳基；R.sub.2 =环烷基、芳基、C.sub.3-C.sub.10烷基；X、Y=O、S(O).sub.n、NH；Z=CHO、CO.sub.2R.sub.3、CONHR.sub.4R.sub.5、CN、COR.sub.6、H、卤素、HCN、NHCONR.sub.4R.sub.5、CONR.sub.4OR.sub.5、CONR.sub.4NR.sub.5R.sub.6、1-四氮唑、S(O).sub.nOH、S(O).sub.nNR.sub.3R.sub.4、C.dbd.NOH、C(.dbd.N(OH)NH.sub.2)、OCONR.sub.7R.sub.6、P(O)(OR.sub.4).sub.2、C(.dbd.N(YR.sub.3))R.sub.4、NH.sub.2、SH、OH、OS(O).sub.2R.sub.3、C(.dbd.NYC(.dbd.O)R.sub.3)R.sub.4、C(O)CO.sub.2R.sub.3、C(O)CONR.sub.3R.sub.4、CH(OH)CO.sub.2R.sub.3、CHFCO.sub.2R.sub.3、CF.sub.2CO.sub.2R.sub.3、CH(OH)CONR.sub.3R.sub.4、CF.sub.2CONR.sub.3R.sub.4、C.dbd.NNH.sub.2、C(.dbd.NOC(.dbd.O)R.sub.3)R.sub.4、C(.dbd.NNHC(.dbd.O)R.sub.3)R.sub.4、C(.dbd.NOH)R.sub.3、C(.dbd.NNR.sub.3)R.sub.4、NHC(.dbd.O)R.sub.6或C(O)CONH.sub.2；R.sub.3、R.sub.4、R.sub.5、R.sub.6、R.sub.7=氢、烷基、芳基、芳基烷基、环烷基或氟烷基；或者是结构式I的化合物，如上所述，其中：X、Y=CH.sub.2、O、S(O).sub.n或NH；Z和R.sub.8=CO.sub.2R.sub.3、CONR.sub.3或R.sub.8和Z被串联，使得R.sub.8Z=C(O)NHNHC(O)、(CH.sub.2).sub.mC(.dbd.W)、V(CH.sub.2).sub.mC(.dbd.W)或V.sub.nCH.dbd.CH(CH.sub.2).sub.nC(.dbd.W)；其中V=O、S(O).sub.n、NH；W=O、NOH、NHNH.sub.2、NOC(O)CH.sub.3或NNHC(O)CH.sub.3；n=0-2；m=2-4或其药学上可接受的盐，用于治疗哮喘、过敏和炎症性疾病，以及使用相同的治疗方法和药物组合物。

  公开号：

  US05650444A1

文献信息

• SUBSTITUTED BIPHENYL DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS
  申请人：AMERICAN HOME PRODUCTS CORPORATION

  公开号：EP0745063B1

  公开（公告）日：1999-03-24
• US5650444A
  申请人：——

  公开号：US5650444A

  公开（公告）日：1997-07-22
• US5691376A
  申请人：——

  公开号：US5691376A

  公开（公告）日：1997-11-25
• Substituted biphenyl derivatives
  申请人：American Home Products Corporation

  公开号：US05650444A1

  公开（公告）日：1997-07-22

  A compound of the following structure: ##STR1## wherein, when R.sub.8 =H: R.sub.1 =alkyl, cycloalkyl, arylalkyl, aryl; R.sub.2 =cycloalkyl, aryl, C.sub.3 -C.sub.10 alkyl; X,Y=O, S(O).sub.n, NH; Z=CHO, CO.sub.2 R.sub.3, CONHR.sub.4 R.sub.5, CN, COR.sub.6, H, halo, HCN, NHCONR.sub.4 R.sub.5, CONR.sub.4 OR.sub.5, CONR.sub.4 NR.sub.5 R.sub.6, 1-tetrazole, S(O).sub.n OH, S(O).sub.n NR.sub.3 R.sub.4, C.dbd.NOH, C(.dbd.N(OH)NH.sub.2, OCONR.sub.7 R.sub.6, P(O)(OR.sub.4).sub.2, C(.dbd.N(YR.sub.3))R.sub.4, NH.sub.2, SH, OH, OS(O).sub.2 R.sub.3, C(.dbd.NYC(.dbd.O)R.sub.3)R.sub.4, C(O)CO.sub.2 R.sub.3, C(O)CONR.sub.3 R.sub.4, CH(OH)CO.sub.2 R.sub.3, CHFCO.sub.2 R.sub.3, CF.sub.2 CO.sub.2 R.sub.3, CH(OH)CONR.sub.3 R.sub.4, CF.sub.2 CONR.sub.3 R.sub.4, C.dbd.NNH.sub.2, C(.dbd.NOC(.dbd.O)R.sub.3)R.sub.4, C(.dbd.NNHC(.dbd.O)R.sub.3)R.sub.4, C(.dbd.NOH)R.sub.3, C(.dbd.NNR.sub.3)R.sub.4, NHC(.dbd.O)R.sub.6 or C(O)CONH.sub.2 ; R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7 =hydrogen, alkyl, aryl, aryalkyl, cycloalkyl, or fluoroalkyl; or a compound of Structure I, as just defined, wherein: X,Y=CH.sub.2, O, S(O).sub.n, or NH; Z and R.sub.8 =CO.sub.2 R.sub.3, CONR.sub.3, or R.sub.8 and Z are concatenated such that R.sub.8 Z=C(O)NHNHC(O), (CH.sub.2).sub.m C(.dbd.W), V(CH.sub.2).sub.m C(.dbd.W), or V.sub.n CH.dbd.CH(CH.sub.2).sub.n C(.dbd.W); where V=O, S(O).sub.n, NH; W=O, NOH, NHNH.sub.2, NOC(O)CH.sub.3, or NNHC(O)CH.sub.3 ; n=0-2; and m=2-4 or pharmaceutically acceptable salts thereof, useful in the treatment of asthma, and allergic and inflammatory diseases, as well as methods of treatment and pharmaceutical compositions utilizing the same.

  以下结构的化合物：##STR1## 其中，当R.sub.8 =H时：R.sub.1 =烷基、环烷基、芳基烷基、芳基；R.sub.2 =环烷基、芳基、C.sub.3-C.sub.10烷基；X、Y=O、S(O).sub.n、NH；Z=CHO、CO.sub.2R.sub.3、CONHR.sub.4R.sub.5、CN、COR.sub.6、H、卤素、HCN、NHCONR.sub.4R.sub.5、CONR.sub.4OR.sub.5、CONR.sub.4NR.sub.5R.sub.6、1-四氮唑、S(O).sub.nOH、S(O).sub.nNR.sub.3R.sub.4、C.dbd.NOH、C(.dbd.N(OH)NH.sub.2)、OCONR.sub.7R.sub.6、P(O)(OR.sub.4).sub.2、C(.dbd.N(YR.sub.3))R.sub.4、NH.sub.2、SH、OH、OS(O).sub.2R.sub.3、C(.dbd.NYC(.dbd.O)R.sub.3)R.sub.4、C(O)CO.sub.2R.sub.3、C(O)CONR.sub.3R.sub.4、CH(OH)CO.sub.2R.sub.3、CHFCO.sub.2R.sub.3、CF.sub.2CO.sub.2R.sub.3、CH(OH)CONR.sub.3R.sub.4、CF.sub.2CONR.sub.3R.sub.4、C.dbd.NNH.sub.2、C(.dbd.NOC(.dbd.O)R.sub.3)R.sub.4、C(.dbd.NNHC(.dbd.O)R.sub.3)R.sub.4、C(.dbd.NOH)R.sub.3、C(.dbd.NNR.sub.3)R.sub.4、NHC(.dbd.O)R.sub.6或C(O)CONH.sub.2；R.sub.3、R.sub.4、R.sub.5、R.sub.6、R.sub.7=氢、烷基、芳基、芳基烷基、环烷基或氟烷基；或者是结构式I的化合物，如上所述，其中：X、Y=CH.sub.2、O、S(O).sub.n或NH；Z和R.sub.8=CO.sub.2R.sub.3、CONR.sub.3或R.sub.8和Z被串联，使得R.sub.8Z=C(O)NHNHC(O)、(CH.sub.2).sub.mC(.dbd.W)、V(CH.sub.2).sub.mC(.dbd.W)或V.sub.nCH.dbd.CH(CH.sub.2).sub.nC(.dbd.W)；其中V=O、S(O).sub.n、NH；W=O、NOH、NHNH.sub.2、NOC(O)CH.sub.3或NNHC(O)CH.sub.3；n=0-2；m=2-4或其药学上可接受的盐，用于治疗哮喘、过敏和炎症性疾病，以及使用相同的治疗方法和药物组合物。